Day: September 4, 2022

Poster #1400P will be presented on Sunday, September 11 by Dr. Aaron R. Hansen INDIANAPOLIS, Sept. 04, 2022 (GLOBE NEWSWIRE) — POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, and global access to life-changing radiopharmaceuticals, today announced data will be released at ESMO Congress 2022 in Paris, France about the efficacy and safety of PNT2002 in the lead-in cohort of the SPLASH trial. An abstract is now available on the ESMO congress website at https://cslide.ctimeetingtech.com/esmo2022/attendee/confcal_2/presentation/list?q=1400P, and an e-poster which contains updated data will be published and presented on Sunday, September 11th. The poster is titled “Efficacy and Safety of 177Lu-PNT2002 Prostate-Specific Membrane Antigen (PSMA) Therapy in Metastatic...

Selected recommended phase 2 dose (RP2D) of 480 mg with ongoing enrollment in disease-specific cohorts; maximum tolerated dose (MTD) not reached Stable disease was observed in 10 of 27 evaluable patients in an unselected patient population Comprehensive pharmacodynamic studies indicate the activation of the innate as well as the adaptive immune system Well managed safety profileHEIDELBERG, Germany, Sept. 04, 2022 (GLOBE NEWSWIRE) — Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that an abstract with clinical trial results of its innate cell engager (ICE®) AFM24 has been accepted for a poster presentation at the Congress of the European Society for Medical Oncology (ESMO) from 9-13 September 2022 in Paris. The abstract...

New prevalence figure 22–126% higher than previous estimates Prevalence expected to reach 592 million by 2050 Researchers urge global action on smoking cessation and air pollution reductionBARCELONA, Spain, Sept. 04, 2022 (GLOBE NEWSWIRE) — Over 480 million people worldwide likely suffer from chronic obstructive pulmonary disease, or COPD, according to a late-breaking abstract led by ResMed (NYSE: RMD, ASX: RMD) presented at the European Respiratory Society Congress today.1 This figure is 22–126% higher than today’s most cited estimates, which range from 212–392 million reported over the past decade.2,3,4 COPD is a chronic, progressive disease that restricts a person’s ability to breathe. Early-stage sufferers may use inhaled medications to reduce symptoms. Advanced stages may require supplemental oxygen or mechanical ventilation...